IRITECAN is indicated for the treatment of patients with advanced colorectal cancer:
• in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease,
• as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.
IRITECAN in combination with cetuximab is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type metastatic colorectal cancer, who had not received prior treatment for metastatic disease or after failure of irinotecan-including cytotoxic therapy.
IRINOTECAN in combination with 5-fluorouracil, folinic acid and bevacizumab is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum.